also,
”Other than the small sample size of this pilot study, this observation may be explained by the fact that, although the standard dose of PG used for adult patients with chronic hepatitis B is generally 30 mg/d, 14 this dose may be insufficient to inhibit CCR2 in the context of diabetes in humans. Treatment adherence of participants assigned to the PG group may not have been sufficient, as indicated by plasma PG concentrations, which were lower than the limit of detection for some patients.”
so they couldn’t even detect PG in some patients assigned to PG treatment...
General Discussion, page-38
-
- There are more pages in this discussion • 97 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
44.0¢ |
Change
0.030(7.32%) |
Mkt cap ! $242.2M | |||
| Open | High | Low | Value | Volume |
| 42.0¢ | 45.8¢ | 42.0¢ | $1.241M | 2.815M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 21639 | 43.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 44.5¢ | 14976 | 2 |
View Market Depth
| Last trade - 16.10pm 14/08/2024 (20 minute delay) ? |
| DXB (ASX) Chart |